ERBB2 and neoplasm: Eight patients in the pre-OSNA group and 2 patients in the post-OSNA group with aggressive tumour biology (Grade III, triple-negative, or HER-2-positive) did not receive chemotherapy due to factors such as age, comorbidities, or patients' choice.